Menopause is one of the largest unmet needs in women’s health. In a recent survey of nearly 5000 women aged 45 to 60, more than one in five said they were not aware of effective options to manage their menopausal symptoms. And when women do try a menopause supplement and then stop taking it, it is mostly because it simply did not work.
Gyntima® Menopause was designed to change that, acting from the gut. Since last year, the formula has collected five independent recognitions across the globe. Each one looked at the science, the innovation and the consumer need, and each one reached the same conclusion: this is a different way to support women through the menopause transition.
Two years of recognition
NutraIngredients Awards: winner in Europe and the US, finalist in Asia
Gyntima® Menopause has been recognized in the Ingredient of the Year – Microbiome Modulation category of all three editions of the NutraIngredients Awards.
- NutraIngredients Awards 2025 (Europe) – Winner. Announced in May 2025 at the ceremony in Barcelona. The judges required solid scientific evidence and clear commercial data for every entry, and described Gyntima® Menopause as “the first probiotic blend shown to maintain estrogen levels by modulating the estrobolome”.
- NutraIngredients-USA Awards 2025 – Winner. Announced in July 2025 in Chicago. An expert judging panel chose the winners through a multi-stage selection that focused on true innovation, market success and cutting-edge research.
- NutraIngredients Asia Awards 2026 – Finalist. Shortlisted for the APAC edition, whose winners were announced during Vitafoods Asia. Reaching the final in Asia confirms that interest in a gut-based approach to menopause is global.
Winner: NIE New Ingredient Awards 2026
Gyntima® Menopause took first place in the Biotics category of the 2026 Nutrition Industry Executive (NIE) New Ingredient Awards. Now in their 8th edition, the awards highlight science-backed branded ingredients launched in the US since October 2024. Winners are chosen by NIE’s editorial team and a panel of eight independent judges, who assess the research, the consumer need and the overall innovation of each ingredient. The judges singled out the formula’s novel approach to the estrobolome, with one noting that Kaneka Probiotics is at the leading edge of this emerging field.
Selected: CRN Innovation Exchange 2026
Gyntima® Menopause was selected from a competitive pool of applicants to present at the Council for Responsible Nutrition’s “Innovation Exchange”, held on 6 October 2026 in Carlsbad, California. The lineup was chosen by a selection committee of industry experts, who selected presentations for both their scientific rigor and their relevance to the market. Jordi Riera, Chief Business Officer of Kaneka Probiotics, presented the session “Reframing Menopause: A Precision Probiotic Approach Targeting the Estrobolome”.
Why Gyntima® Menopause stands out
It works with the body’s own estrogen. Most menopause solutions replace or boost hormones from the outside. Gyntima® Menopause takes a different route: it supports the estrobolome, the community of gut bacteria that helps regulate how much estrogen the body recirculates or eliminates.
It is backed by clinical evidence. The formula is a patented blend of three strains: Levilactobacillus brevis KABP® 052, Lactiplantibacillus plantarum KABP® 051, and Pediococcus acidilactici KABP® 021. It is the first and only commercially available probiotic ingredient to clinically demonstrate both estrogen modulation and an improvement in menopausal symptoms.
It now carries one name worldwide. Gyntima® was pioneered by AB-BIOTICS almost 20 years ago. With Kaneka Probiotics adopting the Gyntima® brand in the United States, our women’s health portfolio now has one name and one body of science in every market.
What’s next
Five independent recognitions in two years give partners and formulators a strong signal: Gyntima® Menopause combines a novel mechanism, clinical evidence and a real consumer need. Together with Kaneka Probiotics, we will keep building the science, with two new large studies already ongoing and more in the pipeline across our Gyntima® women’s health portfolio.
Want to bring Gyntima® Menopause to your market? Contact our team at hello@ab-biotics.com to learn more.